Corcept Therapeutics Incorporated (CORT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Corcept Therapeutics Incorporated (CORT) is up 129.1% since the beginning of the year. At $80 per share, CORT is trading 12.4% below its 52-week high of $91. Investors who bought $1,000 worth of CORT shares 5 years ago would now be looking at an investment worth $3,581.

Corcept Therapeutics Incorporated (CORT) has returned 129.05% so far this year and 11.67% over the past 12 months. Looking at the last ten years, CORT has achieved an annualized return of 31.34%, outperforming the S&P 500 Index benchmark, which averaged 13.88% per year.

Based on dividend-adjusted daily data since Apr 14, 2004, CORT's average daily return is +0.15%, while the average monthly return is +2.83%. At this rate, an investment would double in approximately 2.1 years.

Historically, 49% of months were positive and 51% were negative. The best month was Jun 2007 with a return of +97.1%, while the worst month was Aug 2006 at -67.7%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.

On a daily basis, CORT closed higher 49% of trading days. The best single day was Mar 31, 2025 with a return of +109.1%, while the worst single day was Aug 25, 2006 at -56.0%.

Corcept Therapeutics Incorporated has an annualized alpha of 30.72%, beta of 0.95, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since April 14, 2004.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (77.66%) than losses (75.14%) - typical of diversified or defensive assets.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CORT ranks 50 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Corcept Therapeutics Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Corcept Therapeutics Incorporated was 94.29%, occurring on Oct 13, 2006. Recovery took 2672 trading sessions.

The current Corcept Therapeutics Incorporated drawdown is 30.21%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Corcept Therapeutics Incorporated over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Corcept Therapeutics Incorporated is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.